Phosphate Binders

A dialysis patient's phosphorus is 7.2 mg/dL and climbing. The danger isn't the number itself — it's the calcium-phosphate crystals silently calcifying blood vessels and heart valves.

In chronic kidney disease (CKD), the kidneys lose the ability to excrete phosphorus, leading to hyperphosphatemia (normal: 2.5–4.5 mg/dL). Elevated phosphorus binds circulating calcium, forming calcium-phosphate deposits in soft tissues, blood vessels, and cardiac valves — dramatically increasing cardiovascular mortality. Phosphate binders work in the GI tract, not systemically. They bind dietary phosphorus in the intestine during digestion, forming insoluble complexes excreted in stool. This is why timing is everything: they must be taken WITH meals, not on an empty stomach. Calcium acetate (PhosLo) uses calcium as the binding ion — effective but adds a calcium load, which risks hypercalcemia, especially if the patient also takes vitamin D analogs. Sevelamer (Renagel/Renvela) is calcium-free and lipid-lowering, making it preferred when calcium levels are already elevated or when the patient is on active vitamin D therapy. Both agents reduce GI absorption of many co-administered drugs, so other oral medications should be separated by at least 1–2 hours.

Key Distinctions

Don't confuse phosphate binders with antacids — calcium carbonate (Tums) can act as both, but the clinical intent and dosing timing differ entirely. Students often place phosphate binders at bedtime like a statin; they are useless without food because there is no dietary phosphorus to bind. Sevelamer is chosen over calcium-based binders when serum calcium is high — picking the wrong agent worsens vascular calcification.

Clinical Pearl

No meal, no binder. Phosphate binders are fork-and-knife drugs — they work only when swallowed with food, binding phosphorus right at the table.